Public Consultation: DRAFT 2025 Clinical Guidelines for the Early Detection of Prostate Cancer

Prostate Cancer Foundation of Australia (PCFA) is seeking approval under section 14A of the National Health and Medical Research Council Act 1992 for the DRAFT 2025 Clinical Guidelines for the Early Detection of Prostate Cancer.

The DRAFT 2025 Guidelines are designed to supersede the 2016 Clinical Practice Guidelines for PSA Testing, recognising that significant advancements in diagnosis and treatment have created an evidence-based pathway for a more structured testing program

As part of the approval process, PCFA is inviting feedback from Australian stakeholders on the DRAFT 2025 Guidelines.

Who can make a submission?

Anyone with an interest in prostate cancer is invited to make a submission. This includes:

  • People concerned about the risk of prostate cancer
  • People interested in testing for prostate cancer
  • Health professionals
  • Consumer organisations
  • Policy makers
  • Any member of the public

Responses can be from individuals or on behalf of an organisation/group.

How can I make a submission?

Consultation on the DRAFT 2025 Guidelines will open Monday, April 14, 2025, and will close on Sunday, May 25, 2025 (11:59pm). Submissions can be made online via this form: pcfa.org.au/psa-guidelines-review

Information for your submission

For information about the public consultation process and what type of feedback will be considered click here:

The consultation material can be accessed here:

Other information you may find helpful:

If you have difficulty accessing the content, contact PCFA by emailing: research@pcfa.org.au

Please provide a summary and description of the location of the web page or content in question so we can send an alternate format of the content where possible.